Sort
21,453 grants matching “tuberculosis”
MGMT OF INFO RESOURCES ON THERAPEUTIC AGENTS FOR HIV AND OPPORTUNISTIC INFECTIONS
$860,506Margaret Rush · Gryphon Scientific, Llc · N01 · FY2011 · AI
VACCINE TREATMENT AND EVALUATION UNITS - PHASE I CLINICAL TRIAL TO EVALUATE TB THERAPEUTICS
$860,187Daniel Hoft · Saint Louis University · N01 · FY2018 · AI
Risk of Neonatal Vaccination for HIV/SIV Exposed Infants
$860,114Donald L Sodora · Seattle Biomedical Research Institute · R01 · FY2015 · DE
Combatting natural resistance and persistence in non-TB mycobacterial disease
$859,392Thomas Dick · Hackensack University Medical Center · R01 · FY2019 · AI
Biodiversity of Vietnam and Laos
$858,757Djaja D Soejarto · University Of Illinois At Chicago · U01 · FY2007 · TW
A New Class of Broad-Spectrum Antibacterial Agents to Treat Multi-Drug Resistant Pathogens
$858,436Paul Sebahar · Curza Inc · R44 · FY2025 · AI
Gene Regulation In The Immune System
$857,846Keiko Ozato · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2012 · HD
Optimization of rifamycins to overcome intrinsic resistance of nontuberculous mycobacteria to improve treatment of NTM lung disease
$857,555Thomas Dick · Hackensack University Medical Center · R01 · FY2023 · AI
Transporter function of the Mycobacterium tuberculosis PE/PPE proteins
$857,231Christoph Grundner · Seattle Children'S Hospital · R01 · FY2025 · AI
Development of an engineered CCL20 protein as a lead therapeutic molecule for psoriasis
$856,782Chad Allen Koplinski · Xlock Biosciences, Llc · R44 · FY2020 · AR
Development of Novel Proteins Synthesis Inhibitors for MDR Tuberculosis
$856,731Richard Edward Lee · St. Jude Children'S Research Hospital · R01 · FY2018 · AI
The Rv2623-Rv1747 interaction: regulation of the in vivo fate of M. tuberculosis
$856,524John R. Chan · Rutgers Biomedical And Health Sciences · R01 · FY2023 · AI
RePORT International Consortia: Cross consortia studies elucidating the role of HIV in TB immunopathogenesis and biomarker discovery across Brazil, India and South Africa
$855,852Amita Gupta · National Institute Of Allergy And Infectious Diseases · Y01 · FY2017 · AI
Conservation and Sustainable Use of Biodiversity in PNG
$855,825Louis R Barrows · University Of Utah · U01 · FY2011 · TW
Conservation and Sustainable Use of Biodiversity in PNG
$855,825Louis R Barrows · University Of Utah · U01 · FY2012 · TW
Vaccine and Treatment Evaluation Unit at Saint Louis University
$855,721Daniel F. Hoft · Saint Louis University · UM1 · FY2023 · AI
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
$855,091Joel D. Ernst · University Of California, San Francisco · R01 · FY2023 · AI
Chemotherapeutics Against Multi-Drug Resistant Tuberculosis
$854,641Peter J Tonge · State University New York Stony Brook · U01 · FY2009 · AI
Closing the Gaps on Buruli Ulcer Diagnosis, Treatment, and Prevention
$853,989Eric L Nuermberger · Johns Hopkins University · R01 · FY2020 · AI
Optimal tuberculosis screening and tuberculosis preventive therapy delivery strategies to improve maternal and birth outcomes among pregnant women with HIV in Uganda: a randomized trial
$853,975Christina Yoon · University Of California, San Francisco · R61 · FY2025 · HL
TUBERCULOSIS ELIMINATION AND LABORATORY PROGRAM FUNDING
$853,725Barry Dickman · Philadelphia Departmentof Public Health · U52 · FY2012 · PS
Clinical Trial Site Monitoring for PHOENIx MDR-TB
$853,039Kimberly Smith · Ppd Development Lp · N01 · FY2020 · AI
DISSEMINATED TUBERCULOSIS IN HIV INFECTION
$852,665Dartmouth College · R01 · FY2002 · AI
Core E Animal Infection Models
$852,328David S Perlin · Hackensack University Medical Center · U19 · FY2021 · AI
Genetic, Metabolic and Regulatory Control of MIC and Relapse in M. tuberculosis
$851,389David R Sherman · University Of Washington · R01 · FY2020 · AI